-
公开(公告)号：US10457703B2
公开(公告)日：2019-10-29
申请号：US15085800
申请日：2016-03-30
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10364267B2
公开(公告)日：2019-07-30
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US20170334893A1
公开(公告)日：2017-11-23
申请号：US15597417
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Bin Wang , Yong He , Xuechao Xing , Ruichao Shen , Brett Granger , Jing He , Jiang Long , Guoqiang Wang
IPC: C07D413/12 , C07D261/08
CPC classification number: C07D413/12 , A61K31/42 , C07D261/08
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170304270A1
公开(公告)日：2017-10-26
申请号：US15497268
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Brett Granger , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D261/06 , C07D413/04 , C07D413/12
CPC classification number: A61K31/42 , C07D261/06 , C07D261/08 , C07D413/04 , C07D413/12
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
55.发明申请公开(公告)号：US20170240587A1
公开(公告)日：2017-08-24
申请号：US15439531
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Jing He , Guoqiang Wang , Xuechao Xing
IPC: C07J43/00
CPC classification number: C07J43/003 , A61K31/58 , C07J9/005 , C07J41/0061
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
Patent Agency Ranking
56.发明申请公开(公告)号：US20160130297A1
公开(公告)日：2016-05-12
申请号：US14934122
申请日：2015-11-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Ruichao Shen , Xuechao Xing
CPC classification number: C07J41/0061 , C07J41/0088 , C07J43/003
Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和m如本文所定义，包含这些化合物的药物组合物和使用方法 的这些化合物用于治疗TGR5介导的疾病或病症。
-
公开(公告)号：US11555032B2
公开(公告)日：2023-01-17
申请号：US16871551
申请日：2020-05-11
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Jun Ma , Bin Wang , Ruichao Shen , Xuechao Xing , Yong He , Yat Sun Or
IPC: C07D417/12 , C07D413/12 , C07D417/14 , C07D261/08 , C07D413/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US11420976B2
公开(公告)日：2022-08-23
申请号：US17155159
申请日：2021-01-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yong He , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Brett Granger , Jiang Long , Yat Sun Or
IPC: C07D491/048 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20220162231A1
公开(公告)日：2022-05-26
申请号：US17531844
申请日：2021-11-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jun Ma , Yong He , Xuechao Xing , Hui Cao , Xuri Gao , Xiaowen Peng , Joseph D. Panarese , Yat Sun Or
IPC: C07D519/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220119398A1
公开(公告)日：2022-04-21
申请号：US17503626
申请日：2021-10-18
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Yong He , Kevin McGrath , Ruichao Shen , Adam Szymaniak , Xuechao Xing , In Jong Kim , Guoqiang Wang
IPC: C07D491/048 , A61P31/14 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
94
records
(took 0.026 seconds)
